D. Boral Capital Reiterates “Hold” Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “hold” rating reaffirmed by equities research analysts at D. Boral Capital in a note issued to investors on Tuesday, MarketBeat.com reports.

PSTV has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $1.00 target price (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Finally, Lake Street Capital initiated coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.60.

Plus Therapeutics Stock Performance

Shares of PSTV opened at $0.16 on Tuesday. The firm has a market cap of $26.73 million, a P/E ratio of -0.13 and a beta of 0.79. Plus Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.22. The firm’s 50 day moving average price is $0.26 and its two-hundred day moving average price is $0.46.

Institutional Trading of Plus Therapeutics

Several large investors have recently modified their holdings of PSTV. Susquehanna International Group LLP bought a new stake in shares of Plus Therapeutics during the 3rd quarter valued at approximately $46,000. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics during the second quarter worth $41,000. State Street Corp increased its holdings in shares of Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after buying an additional 127,000 shares in the last quarter. Scientech Research LLC bought a new position in shares of Plus Therapeutics in the 3rd quarter valued at $100,000. Finally, XTX Topco Ltd bought a new position in shares of Plus Therapeutics in the 4th quarter valued at $127,000. 3.28% of the stock is owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.